The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
Abstract
PURPOSE: To evaluate the relative effect of percent maximal cytoreductive surgery and other prognostic variables on survival among cohorts of patients with advanced-stage ovarian carcinoma treated with platinum-based chemotherapy. MATERIALS AND METHODS: Eighty-one cohorts of patients with stage III or IV ovarian carcinoma (6,885 patients) were identified from articles in MEDLINE (1989 through 1998). Linear regression models, with weighted correlation calculations, were used to assess the effects on log median survival time of the proportion of each cohort undergoing maximal cytoreduction, dose-intensity of the platinum compound administered, proportion of patients with stage IV disease, median age, and year of publication. RESULTS: There was a statistically significant positive correlation between percent maximal cytoreduction and log median survival time, and this correlation remained significant after controlling for all other variables (P < .001). Each 10% increase in maximal cytoreduction was associated with a 5.5% increase in median survival time. When actuarial survival was estimated, cohorts with ≤ 25% maximal cytoreduction had a mean weighted median survival time of 22.7 months, whereas cohorts with more than 75% maximal cytoreduction had a mean weighted median survival time of 33.9 months—an increase of 50%. The relationship between platinum dose-intensity and log median survival time was not statistically significant. CONCLUSION: During the platinum era, maximal cytoreduction was one of the most powerful determinants of cohort survival among patients with stage III or IV ovarian carcinoma. Consistent referral of patients with apparent advanced ovarian cancer to expert centers for primary surgery may be the best means currently available for improving overall survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greenlee, R. T., Hill-Harmon, M. B., Murray, T., & Thun, M. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.1.15 · Cited by 3,288
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Impact of Hospital Volume on Operative Mortality for Major Cancer Surgery
Begg, C. B. (1998) · JAMA · doi:10.1001/jama.280.20.1747 · Cited by 1,657
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Hillner, B. E., Smith, T. J., & Desch, C. E. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2327 · Cited by 638
Hoskins, W. J., Bundy, B. N., Thigpen, J. T., & Omura, G. A. (1992) · Gynecologic Oncology · doi:10.1016/0090-8258(92)90100-w · Cited by 544
Eisenkop, S. M., Friedman, R. L., & Wang, H.-J. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1998.4955 · Cited by 507
Primary cytoreductive surgery for epithelial ovarian cancer.
Hacker, N. F., Berek, J. S., Lagasse, L. D., Nieberg, R. K., & Elashoff, R. M. (1983) · PubMed · Cited by 437
Harmon, J. W., Tang, D. G., Gordon, T. A., Bowman, H. M., Choti, M. A., Kaufman, H. S., Bender, J. S., Duncan, M. D., Magnuson, T. H., Lillemoe, K. D., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00013 · Cited by 394
Jodrell, D. I., Egorin, M. J., Canetta, R. M., Langenberg, P., Goldbloom, E. P., Burroughs, J. N., Goodlow, J. L., Tan, S., & Wiltshaw, E. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.520 · Cited by 381
Omura, G. A., Bundy, B. N., Berek, J. S., Curry, S., Delgado, G., & Mortel, R. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.457 · Cited by 321
Management of ovarian cancer: referral to a multidisciplinary team matters
Junor, E., Hole, D., & Gillis, C. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.307 · Cited by 275
Junor, E. J., Hole, D. J., McNulty, L., Mason, M., & Young, J. (1999) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1999.tb08137.x · Cited by 222
Specialists Achieve Better Outcomes Than Generalists for Lung Cancer Surgery
Silvestri, G. A., Handy, J., Lackland, D., Corley, E., & Reed, C. E. (1998) · Chest · doi:10.1378/chest.114.3.675 · Cited by 220
Makar, A. P., Baekelandt, M., Tropé, C. O., & Kristensen, G. B. (1995) · Gynecologic Oncology · doi:10.1006/gyno.1995.1027 · Cited by 219
McGuire, W. P., Hoskins, W. J., Brady, M. F., Homesley, H. D., Creasman, W. T., Berman, M. L., Ball, H., Berek, J. S., & Woodward, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1589 · Cited by 213
Carney, M. E., Lancaster, J. M., Ford, C. D., Tsodikov, A. D., & Wiggins, C. L. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2001.6460 · Cited by 209
A Critique of Surgical Cytoreduction in Advanced Ovarian Cancer
Covens, A. L. (2000) · Gynecologic Oncology · doi:10.1006/gyno.2000.5926 · Cited by 183
The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma
Kehoe, S., Powell, J., Wilson, S., & Woodman, C. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.440 · Cited by 163
Hakes, T. B., Chalas, E., Hoskins, W. J., Jones, W. B., Markman, M., Rubin, S. C., Chapman, D., Almadrones, L., & Lewis, J. L. (1992) · Gynecologic Oncology · doi:10.1016/0090-8258(92)90305-3 · Cited by 162
Bertelsen, K., Jakobsen, A. K. M., Strøyer, I., Nielsen, K. V., Sandberg, E., ANDERSEN, J. E., AHRONS, S., Nyland, M., Pedersen, P. H., Larsen, G., et al. (1993) · Gynecologic Oncology · doi:10.1006/gyno.1993.1081 · Cited by 152
Randomized Trial in Advanced Ovarian Cancer Comparing Cisplatin and Carboplatin
Mangioni, C., Bolis, G., Pecorelli, S., Bragman, K., Epis, A., Favalli, G., Gambino, A., Landoni, F., Presti, M., Torri, V., et al. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.19.1464 · Cited by 142
Ovarian cancer staging: Does it require a gynecologic oncologist?
Mayer, A. R., Chambers, S. K., Graves, E., Holm, C. T., Tseng, P. C., Nelson, B. E., & Schwartz, P. E. (1992) · Gynecologic Oncology · doi:10.1016/0090-8258(92)90110-5 · Cited by 139
Voest, E. E., van Houwelingen, H. C., & Neijt, J. P. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90208-3 · Cited by 89
Taylor, A., Wiltshaw, E., Gore, M. E., Fryatt, I., & Fisher, C. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2066 · Cited by 77
Averette, H. E., Hoskins, W. J., Nguyen, H. N., Boike, G. M., Flessa, H. C., Chmiel, J. S., Zuber, K., Karnell, L. H., & Winchester, D. P. (1993) · PubMed · Cited by 72
Perren, T. J., Wiltshaw, E., Harper, P., et al. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.502 · Cited by 10
Cited by
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Self-citationNeoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Ovarian Cancer Development and Metastasis
Lengyel, E. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,672
du Bois, A., Reuss, A., Pujade‐Lauraine, E., Harter, P., Ray‐Coquard, I., & Pfisterer, J. (2009) · Cancer · doi:10.1002/cncr.24149 · Cited by 1,638
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Metadata
- Authors
- Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-03-01
- Volume
- 20
- Issue
- 5
- Pages
- 1248-1259
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2099521317
- Cited by
- 2,312
- References
- 27
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.